The Mounjaro 10mg pen: what changes at this dose?

Why does the licensed schedule include a 10mg step at all?

Tirzepatide's titration ladder exists to reduce side effects, not to delay results. Your body needs time to adjust to a medicine that simultaneously slows gastric emptying and amplifies two appetite-regulating hormones. Moving too fast tends to produce more nausea and vomiting; moving in measured steps means most people tolerate each new dose with minimal disruption before they reach a level that does meaningful therapeutic work.

The 10mg pen sits at a point where many people start to see their appetite suppression deepen noticeably. The NHS tirzepatide medicines page describes the standard titration pattern: four weeks at each strength, with the prescriber reviewing tolerance and progress before a step-up is confirmed. That review matters. If someone is still experiencing significant nausea at 7.5mg, moving to 10mg may be postponed. If they are tolerating 7.5mg well and weight loss has plateaued, 10mg is the natural next stage.

It is also worth understanding what the pen itself does mechanically. The KwikPen delivers a fixed 10mg dose with a single injection; if you want to understand how that 10mg dose translates into millilitres of liquid, that page explains the volume in practical terms. For detail on how the dose mechanism works, this page on pen clicks at 10mg covers the device in practical terms.

What does the evidence say about weight loss at 10mg?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three tirzepatide doses: 5mg, 10mg and 15mg. At 10mg, participants lost an average of around 19.5% of their body weight over 72 weeks. That figure sits between the 5mg result (roughly 15%) and the 15mg result (around 20–21%), which is what you would expect from a dose-response relationship.

A few caveats matter here. Trial participants followed a reduced-calorie diet and increased their activity, the same two lifestyle elements that Mounjaro's licence requires alongside the injection. Results outside that structured environment vary. Weight loss also tends to be gradual: the steepest losses typically appear in the first six months, with the rate slowing as the body adjusts.

If you are curious about how 10mg compares to the earlier 5mg pen, the 5mg page covers that dose's place in the schedule. NICE's appraisal of tirzepatide (TA1026) also draws on SURMOUNT data to inform the recommendation, the TA1026 guidance is worth reading for context on how the medicine fits into UK clinical practice.

What side effects are more likely at this dose, and when should you get medical help?

The GI side effects associated with tirzepatide (nausea, loose stools, constipation, reflux, burping) are most prominent when a dose increases. For some people, the jump to 10mg is uneventful. For others, the first week or two at this strength brings a return of symptoms they thought had settled. That pattern is normal and usually temporary.

Practical help: smaller, lower-fat meals and staying well hydrated make a genuine difference during the adjustment window. A question our prescribers hear regularly is whether fizzy drinks make nausea worse at higher doses; there is a useful read on diet drinks and Mounjaro if that applies to you.

Some symptoms need prompt medical attention rather than patience. Severe stomach pain that radiates towards the back (particularly when it does not ease and is accompanied by vomiting) can indicate pancreatitis, which is a known but infrequent risk with GLP-1 medicines. Seek urgent help if that happens. The same applies to signs of a serious allergic reaction or symptoms of dehydration following persistent vomiting or diarrhoea. Suspected side effects can be reported through the MHRA Yellow Card scheme.

On storage: the pen lives in the fridge at 2–8°C between uses. Keeping it in the fridge door alongside everyday items makes it easy to remember, but check the patient information leaflet for the exact guidance on temperature, light exposure and how long a pen can safely sit at room temperature if needed, the leaflet, not a general article, is the authority on those details.

Who is likely to be prescribed the 10mg pen, and how does that decision get made?

Reaching 10mg is not automatic. It follows a prescriber's review of how you responded to 7.5mg: weight loss trajectory, any ongoing side effects, and whether the dose increase is clinically appropriate for you at that point. Private eligibility for Mounjaro broadly covers adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, but a number is never the whole picture, and prescribers assess the full clinical context.

For a detailed look at the 10mg dose as a monthly prescription, the 10mg overview page covers eligibility and what to expect from a full course at this strength. If you are considering treatment for the first time rather than a step-up, the Mounjaro overview is a good starting point, and the weight-loss treatments page explains how a consultation with our prescribers works.

Mounjaro is not available through most NHS routes unless you meet the current phased criteria under NICE TA1026, which involve a specific BMI threshold and multiple weight-related conditions. Private treatment through a GPhC-registered pharmacy fills that gap for people who do not yet qualify or prefer not to wait. If you think 10mg might be the right next step, or you want a prescriber to review whether Mounjaro is right for you at all, checking your eligibility is the place to start.